Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin

Annals of Pharmacotherapy

Volumn 43, Issue 11, 2009, Pages 1765-1773

  Cheetham, T Craig ^a   Levy, Gerald ^b   Niu, Fang ^a   Bixler, Felicia ^c  

^a Pharmacy Analytic Services   (United States)

^b KAISER PERMANENTE   (United States)

^c Kaiser Permanente Southern California   (United States)

Author keywords

Antiinflammatory agents, nonsteroidal; Drug interaction; Gastrointestinal bleeding; Safety; Selective cyclooxygenase inhibitors; Warfarin

Indexed keywords

CELECOXIB; CITALOPRAM; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ESCITALOPRAM; ETODOLAC; FLUOXETINE; FLUVOXAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PROTON PUMP INHIBITOR; ROFECOXIB; SERTRALINE; SUCRALFATE; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON PROFIT ORGANIZATION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; WARFARIN;

EID: 70449702048     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M284     Document Type: Article

References (35)

1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165: 1095-1106 DOI 10.1001/archinte.165.10.1095
2. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328 DOI 10.1016/0002-9343(93)90285-W
3. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-466 DOI 10.1136/gut.35.4.464
4. Tabibian N. Acute gastrointestinal bleeding in anticoagulated patients: a prospective evaluation. Am J Gastroenterol 1989;84:10-12
5. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med 1988;84:683-690 DOI 10.1016/0002-9343(88)90105-2
6. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal antiinflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-1670 DOI 10.1001/archinte.153.14.1665
7. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995;29:1274-1283
8. Knijff-Dutmer EA, Schut GA, van de Laar MA. Concomitant coumarin - NSAID therapy and risk for bleeding. Ann Pharmacother 2003;37:12-16 DOI 10.1345/aph.1C157
9. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug - drug interactions with a prescription claims database. Am J Health-Syst Pharm 2005;62:1983-1991 DOI 10.2146/ajhp040567
10. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-1602 DOI 10.1002/1529-0131(199809)
11. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40:124-132 DOI 10.1177/00912700022008766
12. Product information. Celebrex (celecoxib). New York, NY: Pfizer, Inc., February 2007.
13. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003;52:820-826 DOI 10.1136/gut.52.6.820
14. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001;15:1593-1601 DOI 10.1046/j.1365-2036.2001.01007.x
15. Scheiman JM, Cryer B, Kimmey MB, Rothstein RI, Riff DS, Wolfe MM. A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin Gastroenterol Hepatol 2004;2: 290-295 DOI 10.1016/S1542-3565(04) 00057-6
16. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-1027 DOI 10.1111/j.1572-0241.2001.03740.x (Pubitemid 32319131)
17. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-2111 DOI 10.1016/S0140-6736(99)02332-6 (Pubitemid 30008893)
18. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-1928 DOI 10.1001/jama.282.20.1921
19. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000;40:655-663 DOI 10.1177/00912700022009305
20. Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 2000;68:626-636 DOI 10.1067/mcp.2000.112244 (Pubitemid 32059989)
21. Dentali F, Douketis JD, Woods K, et al. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann Pharmacother 2006;40:1241-1247 Epub 27 Jun 2006. DOI 10.1345/aph.1G733 (Pubitemid 44204951)
22. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin (letter). Ann Pharmacother 2000;34:666-667 DOI 10.1345/aph.19324 (Pubitemid 30257497)
23. Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health-Syst Pharm 2001;58:2076-2080
24. Stoner SC, Lea JW, Dubisar BM, Farrar C. Possible international normalized ratio elevation associated with celecoxib and warfarin in an elderly psychiatric patient. J Am Geriatr Soc 2003;51:728-729 DOI 10.1034/j.1600-0579. 2003.00228.x (Pubitemid 36541447)
25. Linder JD, Monkemuller KE, Davis JV, Wilcox CM. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000;93:930-932
26. Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000;34:325-327 DOI 10.1345/aph.19246
27. Malhi H, Atac B, Daly AK, Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J 2004;80:107-109 DOI 10.1136/pmj.2003.006478 (Pubitemid 38297245)
28. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165:189-192 DOI 10.1001/archinte.165.2.189
29. Chung L, Chakravarty EF, Kearns P, Wang C, Bush TM. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther 2005;30:471-477 DOI 10.1111/j.1365-2710.2005.00676.x (Pubitemid 41603022)
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55. DOI 10.1093/biomet/70.1.41
31. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281 DOI 10.1002/(SICI)1097-0258
32. Perkins SM, Tu W, Underhill MG, Zhou XH, Murry MD. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000;9:93-101. DOI 10.1002/(SICI)1099-1557 (Pubitemid 30307349)
33. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002;137:693-695
34. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-481 DOI 10.1016/S0140-6736(05)17864-7 (Pubitemid 40215729)
35. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073 DOI 10.1161/01.CIR.0000127578.21885.3E (Pubitemid 38620213)